<DOC>
	<DOCNO>NCT00130494</DOCNO>
	<brief_summary>This open-label , randomize , multicenter phase III trial ass efficacy early administration zoledronate versus observation delay bone-related symptom metastatic breast cancer patient . Patients randomise receive 4 mg zoledronate every 3-4 week versus observation bone-related symptom appear , 12 month . One hundred twelve patient per treatment arm enrol study . Once bone-related symptom appear , study participation . During study , follow assess : - quality life , - performance status , - pain rating , - analgesic administration - adverse event The principal objective delay bone-related symptom patient early zoledronate administration .</brief_summary>
	<brief_title>Zoledronic Acid Administration Metastatic Breast Cancer Patients With Non-Symptomatic Bone Lesions</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Written inform consent . Age &gt; = 18 year old . Metastatic breast cancer patient lytic , sclerotic mixed bone lesion . Nonsymptomatic bone lesion , define pain absence , lack bone complication ( fracture , hypercalcemia , central nervous system [ CNS ] compression ) , need analgesic chronic administration bone disease . A maximum two chemotherapy line metastatic disease . A maximum two hormone therapy line metastatic disease . Normal , minimally alter renal function ( serum creatinine &lt; 1.5 x upper normal limit [ UNL ] ) . Normal serum calcium level . Performance status 0,1 ( World Health Organization [ WHO ] ) . Negative pregnancy test study recruitment . Previous treatment bisphosphonates raloxifene 30 day prior randomization . Metastasis CNS . History hypersensitivity bisphosphonates . Pregnant lactating woman . Third chemotherapy line metastatic disease . Third hormone therapy line metastatic disease . Males .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Non-symptomatic bone metastasis .</keyword>
</DOC>